QA108 Phase III Study in Subjects With Intermediate AMD

PHASE3RecruitingINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

July 8, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

June 30, 2027

Conditions

Intermediate Age-Related Macular Degeneration

Interventions

DRUG

QA108 granules

Take the medication as required for 24 weeks

DRUG

QA108 granules placebo

Take the medication as required for 24 weeks

Trial Locations (1)

RECRUITING

Beijing Hospital, Beijing

All Listed Sponsors

lead

Smilebiotek Zhuhai Limited

INDUSTRY